The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A...

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Vericiguat, a soluble guanylate cyclase (sGC) stimulator, improves cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF).
• The precise mechanisms by which vericiguat exerts its effects in HFrEF remain unclear.
• Endothelial dysfunction is a key feature of HFrEF, impacting cardiovascular health.

Purpose of the Study:

• To assess the feasibility of evaluating vericiguat's impact on endothelial function in HFrEF patients.
• To explore vericiguat's effects on biomarkers and clinical outcomes in HFrEF.

Main Methods:

• A pilot, randomized, double-blind, placebo-controlled trial involving 26 HFrEF patients.
• Assessed feasibility of enrollment, retention, drug titration, and data collection.
• Primary outcome: brachial artery flow-mediated vasodilation (FMD); Secondary outcomes: NT-proBNP, inflammatory markers, functional capacity, and health-related quality of life (hrQOL).

Main Results:

• Feasibility objectives were successfully met with high retention rates.
• Exploratory analysis showed a non-significant trend in FMD improvement (0.7% difference).
• Vericiguat demonstrated a nominally significant reduction in NT-proBNP levels (p=0.03).

Conclusions:

• The study confirms the feasibility of assessing endothelial function in HFrEF patients receiving vericiguat.
• The pilot study's sample size lacked precision to confirm treatment effects on FMD.
• Larger, longer trials are warranted to fully evaluate sGC stimulation's therapeutic potential for endothelial function in HFrEF.